Print
Health Care

PPD's Roles In COVID-19 Work Continue With Milestones

By Christina Haley O'Neal, posted Oct 23, 2020
Moderna is conducting its so-called Phase 3 COVE study to develop a potential vaccine against COVID-19. (Photo courtesy of Moderna)
Wilmington-headquartered PPD Inc. (Nasdaq: PPD) has helped facilitate work as a partner with Moderna in the successful execution of the Phase 3 COVE study of its mRNA vaccine against COVID-19, according to a news release. The firm also played a role in the first federally approved treatment for the coronavirus.

Massachusetts-based Moderna Inc. announced this week the completion of the enrollment of 30,000 participants in what the firm calls its Phase 3 COVE study, officials said.

The Phase 3 study of its mRNA-1273, a vaccine candidate against COVID-19, is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

"To date, more than 25,650 participants have received their second vaccination," stated the release. "Moderna will determine whether to submit a dossier to FDA requesting Emergency Use Authorization based on an assessment of whether the potential benefit of the vaccine outweighs the potential risks once the 2 months of median safety follow-up have accrued."

PPD, a global contract research organization providing drug development, laboratory and lifecycle management services, has been "essential to the successful execution to date of the COVE study," officials said in the release.

PPD also supported Moderna's Phase 2 study of mRNA-1273, stated the release.

The Phase 3 COVE study was designed in collaboration with the FDA and NIH to evaluate those at high risk of severe COVID-19 disease.

As of Thursday, the COVE study includes more than 7,000 people nationwide over the age of 65 and more than 5,000 people under the age of 65, but have high-risk chronic diseases that put them at increased risk of severe COVID-19, including diabetes, severe obesity and cardiac disease.

"These medically high-risk groups represent 42% of the total participants in the Phase 3 COVE study," officials said in the release.

The study also includes more than 11,000 participants from minority communities, representing 37% of the study population, including more than 6,000 participants who identify as Hispanic or LatinX, and more than 3,000 participants who identify as Black or African American.

Phase 3 clinical studies of the Moderna vaccine are taking place across the nation, including in Wilmington with Trial Management Associates, which is working with two physicians, Bart Williams and Will Jones, at Wrightsville Family Practice. Moderna selected the Wilmington-based contract management organization for both Phase 2 and Phase 3 studies this year.

“Completing enrollment of the Phase 3 COVE study is an important milestone for the clinical development of mRNA-1273, our vaccine candidate against COVID-19. We are indebted to all of the participants in the study. We would also like to thank the investigators and our partners at clinical trial sites, including our partners from PPD and the NIH, as well as the dedicated Moderna team for their support in completing enrollment,” said Stéphane Bancel, CEO of Moderna, in the release. “Moderna is committed to rigorous scientific research and the highest data quality standards. We will continue to work in collaboration with regulators to advance mRNA-1273, which we hope will help defeat the COVID-19 pandemic.”

PPD was also a partner in work involving Gilead Sciences' remdesivir, or Veklury, which was recently approved for use in adult and pediatric patients ages 12 and older for the treatment of COVID-19 requiring hospitalization, according to a news release from the FDA.

Veklury is the first treatment for COVID-19 to receive FDA approval, stated the release. 

“I am immensely proud of the dedication of everyone at PPD who helped Gilead achieve this significant outcome with remdesivir," said David Simmons, chairman and CEO of PPD, in a statement on the firm's website. "Together, we all are inspired by the opportunity to help our customers deliver innovative therapies. Our work with Gilead is an excellent example of how we are responding to the critical needs of our customers and our world during the pandemic.”
Ico insights

INSIGHTS

SPONSORS' CONTENT
Dallas headshot 300x300

Don’t Let Your Key Employees Jump Ship

Dallas Romanowski - Cornerstone Business Advisors
Cflc kellygosssechristheadshot

Raising Money In Troubled Times: 6 Ways You Can Help

Kelly Goss Sechrist - Cape Fear Literacy Council
Mikeharrington carolinaretreats 2

Vacation Rental Maintenance: What To Expect

Mike Harrington - Carolina Retreats

Trending News

Wilmington Downtown Inc. Announces New CEO

Cece Nunn - Dec 3, 2020

In Downtown Wilmington, New Office Space Emerges Inside Historical Building

Cece Nunn - Dec 2, 2020

Tama Cafe Closing On Military Cutoff Road In Wilmington

Jessica Maurer - Dec 2, 2020

County Tier Downgrade Could Help More Money Flow Into The Region

Christina Haley O'Neal - Dec 1, 2020

Commercial Space Changing To Residential In Leland Mixed-use Project

Cece Nunn - Dec 3, 2020

In The Current Issue

Making History Work For The Future

Crews are working on making the former fellowship hall at Pearsall Memorial Presbyterian Church, 3902 Market St., into a new office for PBC...


Plantation Village Continues To Cope

Lessons have been learned and changes made at the retirement community of just over 300 residents, ranging in ages from 62 to 100 years old....


Planning Proves Key To Retirement

No matter the amount of your assets, the key to funding retirement is planning – ideally, starting in the years before you clock off the job...

Book On Business

The 2020 WilmingtonBiz: Book on Business is an annual publication showcasing the Wilmington region as a center of business.

Order Your Copy Today!


Galleries

Videos

2020 Leadership Accelerator: Virtual Workshops for Real Leaders
2019 Health Care Heroes
August 26, 2019 Power Breakfast: A Healthy Sale?
2019 WilmingtonBiz Expo Keynote Lunch - CEO, nCino, Pierre Naude`